Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol

Velden, Vincent H.J. van der; Corral, Lilia; Valsecchi, Maria Grazia; Jansen, Mieke; Lorenzo, Paola De; Cazzaniga, Giovanni; Panzer-Grümayer, E. R.; Schrappe, Martin; Schrauder, André; Meyer, Claus; Marschalek, Rolf; Nigro, Luca Lo; Metzler, Markus; Basso, Giuseppe; Mann, Georg; Boer, Monique L. den; Biondi, Andrea; Pieters, R.; Dongen, Jacques J. M. van

doi:10.1038/leu.2009.17

Cited by 140 publications

(123 citation statements)

References 32 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…In addition, genomic break points of some leukemiaspecific translocations, such as MLL gene rearrangements or SIL-TAL1 fusion genes, represent alternative DNA targets; however, they are applicable only to a minority of patients. 41,42 Clone-specific Ig/TCR PCR generally reaches sensitivities of 10 À4 -10 À5 . These high sensitivities require the precise identification of junctional region sequences of Ig and TCR genes in each ALL, because these sequences are required to design clone-specific oligonucleotides.…”

Section: Pcr Analysis Of Ig and Tcr Gene Rearrangementsmentioning

confidence: 99%

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

et al. 2009

Self Cite

View full text Add to dashboard Cite

Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR-and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.

show abstract

Section: Pcr Analysis Of Ig and Tcr Gene Rearrangementsmentioning

confidence: 99%

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two DNA MRD markers with high sensitivity (at least 10 -4 ) are generally required in MRD intervention clinical trials [29][30], and in a large cohort of 2854 pediatric precursor B-cell ALL patients, 20% of patients had only one sensitive marker and 8% had none [30]. At present the concept of using disease-related markers for MRD testing has been already established for fusion transcripts such as BCR-ABL and for gene rearrangements such as for SIL-TAL1 in T-ALL and for MLL rearrangements in infant ALLs [31]. The use of oncogenic lesions for MRD monitoring has been limited by the fact that recurrent chromosomal translocations are not found in all ALL and are usually studied at the RNA level, so that IKZF1 gene deletions will provide a useful addition to the repertoire of MRD markers currently available for monitoring MRD in ALL and inclusion of this marker in standard screening for MRD targets would be an easy way to provide more patients with two sensitive markers.…”

Section: Discussionmentioning

confidence: 99%

High frequency of IKZF1 deletions in Chinese adult patients with acute lymphoblastic leukemia detected by multiplex real-time quantitative PCR

Wu¹,

Zhou²,

Yao³

et al. 2017

Clin Diagn Pathol

View full text Add to dashboard Cite

Objectives: To examine the incidence and clinical dynamics of IKZF1 alterations in Chinese adult patients with ALL.Methods: Samples were studied from 328 newly diagnosed adult ALL patients at Peking University People's Hospital from 2007 to 2012 by multiplex real-time quantitative PCR, multiplex fluorescent PCR and sequence analysis for four types of IKZF1 deletions. Albumin (ALB) was the plasmid standard.Results: All correlation coefficients for amplified ALB(albumin) and IKZF1 Δ4-7 deletion plasmids were above 0.99, and the sensitivity of detection was at least ten copies. About 36.3% (95% [CI], 31.1-41.7%) of 328 untreated cases showed IKZF1-deletion. The median IKZF1-deletion copies/ALB copy was 85.8% (0.1%-697.9%). 27 IKZF1-deletion-positive patients (219 samples in total) were followed up after treatment, among them, 18 patients in hematologic remission continued to be tested negative within 8-66 weeks. In 5 relapsed cases, elevated levels of IKZF1 deletion were detected when relapse occurred. In 4 non responders, IKZF1 deletion maintained at high level. Patient with B-cell ALL subtype had much higher IKZF1-deletion rate (40.4%) than those with T-cell ALL subtype (2.8%, P<0.01). In particular, it was higher in common B-cell ALL group than those with other subtypes. Conclusion:This assay is reliable and sensitive. It is useful in diagnosis and monitoring minimal residual disease in adult ALL. High frequency of IKZF1 deletions occur in adult patients with common B-cell ALL.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Prospective studies in large series of patients have demonstrated a strong correlation between MRD levels during clinical remission and treatment outcome. 10,11 For MRD studies, leukemia-associated immunophenotypes (LAIP) Methods: Fifteen cases of B-ALL were studied for MRD at Day 19 of remission-induction therapy by employing a simplified MRD detection protocol using a 3-color fluorochrome conjugated antibody panel (CD19, CD10, and CD34) on bone marrow aspirate samples.…”

Section: Introductionmentioning

confidence: 99%

Flow cytometric detection of minimal residual disease in B-lineage acute lymphoblastic leukemia by using “MRD lite” panel

Chatterjee

Somasundaram

2017

Medical Journal Armed Forces India

View full text Add to dashboard Cite

IntroductionMinimal residual disease (MRD) refers to the presence of recalcitrant leukemic blasts in the peripheral blood or bone marrow, which is beyond the lower limit of morphologic detection by light microscopy and can only be detected by highly sensitive assays, be it polymerase chain reaction based or flow cytometry based. 1 PCR-based and flow cytometric MRD technologies have been developed over the past two decades with their inherent advantages and disadvantages. 2-9 Detection of MRD would aid in the patient management by either intensifying therapy in MRD positive cases or de-intensifying and thereby reducing treatment-related mortality and morbidity in MRD negative cases. Prospective studies in large series of patients have demonstrated a strong correlation between MRD levels during clinical remission and treatment outcome. 10,11 For MRD studies, leukemia-associated immunophenotypes (LAIP)m e d i c a l j o u r n a l a r m e d f o r c e s i n d i a 7 3 ( 2 0 1 7 ) 5 4 -5 7

show abstract

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol

Cited by 140 publications

References 32 publications

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

High frequency of IKZF1 deletions in Chinese adult patients with acute lymphoblastic leukemia detected by multiplex real-time quantitative PCR

Flow cytometric detection of minimal residual disease in B-lineage acute lymphoblastic leukemia by using “MRD lite” panel

Contact Info

Product

Resources

About